Pathological scores of the pancreas and kidneys following CRAI with 5-Fu and Octreotide (Oct).

<p>Three treatment groups have lower pancreatic pathologic scores than SAP group. Combination using of 5-Fu and Oct significantly improved the pancreatic pathologic scores as compared to the single use of 5-Fu or Oct. Both Oct treatment groups demonstrated lower pathologic scores than the 5-Fu group. No significant pathologic changes were found in the sham group. *: vs. SAP group, P<0.05; ☆: vs. SAP group, P<0.01; $: 5-FU group vs. Oct group, P<0.05;$$: 5-FU group vs. Oct group, P<0.01; #: 5-FU group or Oct group vs. 5-FU + Oct group, P<0.05; ##: 5-FU group or Oct group vs. 5-FU + Oct group, P<0.01.</p

CRAI with 5-Fu and Octreotide (Oct) increased the ratio of TXB₂ to 6-k-PGF_1α.

<p>No significant difference of TXB₂ was found among the 4 experimental groups. However, 6-k-PGF1α significantly increased in all 3 treatment groups. So the ratio of TXB2 to 6-k-PGF1α was significantly lower in the treatment groups as compared to the SAP group. The sham group had normal TXB2, 6-k-PGF1α, and ratio of TXB2 to 6-k-PGF1α. *: vs. SAP group, P<0.05; ☆: vs. SAP group, P<0.01; $: 5-FU group vs. Oct group, P<0.05;$$: 5-FU group vs. Oct group, P<0.01; #: 5-FU group or Oct group vs. 5-FU + Oct group, P<0.05; ##: 5-FU group or Oct group vs. 5-FU + Oct group, P<0.01.</p

Survival time in the various groups.

<p>Group B  =  SAP  =  severe acute pancreatitis.</p><p>Group C  =  SAP + CRAI with 5-FU.</p><p>Group D  =  SAP + CRAI with octreotide.</p><p>Group E  =  SAP + CRAI with 5-FU and octreotide.</p><p><i>P</i> value, the comparison of the statistical value between every two group.</p

CRAI with 5-Fu and Octreotide (Oct) attenuated serum parameters of pancreatitis.

<p>Three treatment groups have lower serum levels of amylase activity, TNF-α and BUN as compared to the SAP group at different time points. The combined use of 5-Fu and Oct significantly decreased the levels of amylase activity as compared to single use of 5-Fu or Oct. Both Oct treatment groups had a lower BUN level as compared to the SAP group. No significant changes of serum levels of amylase activity, TNF-α, Cr and BUN were found in the sham group. *: vs. SAP group, P<0.05; ☆: vs. SAP group, P<0.01; $: 5-FU group vs. Oct group, P<0.05;$$: 5-FU group vs. Oct group, P<0.01; #: 5-FU group or Oct group vs. 5-FU + Oct group, P<0.05; ##: 5-FU group or Oct group vs. 5-FU + Oct group, P<0.01.</p